Pharmaceuticals

Evolution of GMO requirements for innovative investigational medicinal products upon transition to the EU CTR

By , , , , , , and 2023-05-18T12:58:00

adobestock_203962815_edited_689767-DARKER

The EU CTR replaced the EU CTD on 31 January 2022, which impacts investigational medicinal products that fall under genetically modified organisms (GMO-IMPs). This article discusses the specificities of the new CTR process for GMO-IMPs and updates on the GMO application processes in light of these changes.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to TOPRA members and registered users.

If you are a TOPRA member, or have already registered for limited free access, log in now (Option 1 below).

Not yet a member? You can either join TOPRA (Option 2 below) or register to view limited content for free (Option 3 below).

1. LOGIN

Already a TOPRA member?

Log in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.

Already registered for free content?

If you are not a TOPRA member but have already created an account to access limited free content, log in here using your registered user email and password.

Login

2. JOIN TOPRA

Interested in TOPRA membership?

Become a TOPRA member and join our global regulatory affairs community.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.

Become a member

3. REGISTER FOR FREE

Want free access to selected content?

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account